PDS Biotechnology Corp reports results for the quarter ended in June - Earnings Summary

PDS Biotechnology

13/08/2024 14:31

* PDS Biotechnology Corp  PDSB.OQ  reported a quarterly
adjusted
loss of 23 cents​​ per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -37 cents.  The mean expectation of six analysts
for the quarter was for a loss of 34 cents per share. Wall
Street expected results to range from -40 cents to -29 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * PDS Biotechnology Corp's reported EPS for the quarter was
a loss
of 23 cents​.
    * The company reported a quarterly loss of $8.33 million.
    * PDS Biotechnology Corp shares had risen by 4.1% this
quarter and
lost 38.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 7% in
the last three months.​ 
    * In the last 30 days, there have been no negative revisions
of
earnings estimates

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for PDS Biotechnology
Corp is $9.00 
This summary was machine generated from LSEG data August 13 at
01:31 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.34          -0.23          Beat
 Mar. 31 2024      -0.37          -0.30          Beat
 Dec. 31 2023      -0.44          -0.35          Beat
 Sep. 30 2023      -0.45          -0.35          Beat